What is the BiotechSigns catalyst score for AVIR?

AVIR currently has a BiotechSigns catalyst score of 38/100 and grade D. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSigns track for AVIR?

BiotechSigns tracks 0 active signals for AVIR, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the AVIR catalyst page updated?

This AVIR page was refreshed from BiotechSigns data on 2026-06-03.

Atea Pharmaceuticals (AVIR) — FDA PDUFA Catalyst Score

Atea Pharmaceuticals (AVIR) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov^[3], including 2 Phase 3^[1], 1 Phase 1^[2].

Trial NCT06868264^[4] evaluates Bemnifosbuvir-Ruzasvir (BEM/RZR) in HEPATITIS C VIRUS CHRONIC INFECTION with a target enrollment of 880 participants. Trial NCT07037277^[5] evaluates Bemnifosbuvir-Ruzasvir in HEPATITIS C VIRUS CHRONIC INFECTION with a target enrollment of 880 participants.

AVIR has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[6].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT06868264 (2025-12-05) ↗
ClinicalTrials.gov · NCT07037277 (2026-01-20) ↗
SEC EDGAR · 0001593899 (2026-04-11) ↗

AVIR

What is the current AVIR catalyst setup?

Sources